Elevance Health (ELV) Nears Earnings With Long Term Confidence Testing A Fair Value View
Elevance Health (ELV) has completed a long running share repurchase program as investors prepare for an anticipated year over year decline in Q2 earnings and revenue and monitor new institutional interest.
See our latest analysis for Elevance Health.
At a share price of $426.79, Elevance Health has seen firm upward momentum recently, with a 30 day share price return of 5.62% and a 90 day share price return of 37.15%, while the 1 year total shareholder return of 29.61% sits well ahead of its 3 year and 5 year totals as investors weigh the upcoming Q2 results, the completed buyback and the new institutional interest.
If Elevance Health has sharpened your focus on healthcare opportunities, it could be a good moment to widen the lens and review 40 healthcare AI stocks
Bulls point to Elevance Health’s completed buyback and fresh institutional backing, while bears focus on the expected Q2 earnings dip and rich recent share gains. Which story does the current valuation actually support?
Most Popular Narrative: 2.2% Undervalued
The most followed narrative values Elevance Health at $436.52, slightly above the last close at $426.79, which puts recent Q2 worries into a tighter pricing frame.
The analysts have a consensus price target of $436.52 for Elevance Health based on their expectations of its future earnings growth, profit margins and other risk factors.
Given the current share price of $425.17, the analyst price target of $436.52 is 2.6% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
Want to see what sits behind that fair value call? The narrative leans on measured revenue growth, a stronger margin profile, and a lower future earnings multiple than many peers. The exact mix of those inputs may surprise you.
Result: Fair Value of $436.52 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still a real chance that prolonged Medicaid margin pressure or higher than expected medical costs, including specialty drugs and behavioral health, could challenge Elevance Health’s fair value story.
Find out about the key risks to this Elevance Health narrative.
Next Steps
With sentiment on Elevance Health split between caution and optimism, this may be a good time to review the data yourself and make a clear decision. Start by weighing the 4 key rewards
Looking for more investment ideas beyond Elevance Health?
If Elevance Health has sharpened your thinking, do not stop there. Use the same structured approach to compare other opportunities and pressure test your portfolio decisions.
- Spot potential mispricings quickly by scanning 44 high quality undervalued stocks that pair quality fundamentals with compressed valuations.
- Strengthen your income stream by reviewing 8 dividend fortresses that combine higher yields with disciplined payout profiles.
- Reduce portfolio stress by focusing on 79 resilient stocks with low risk scores built around resilient finances and more stable risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com